Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Adjusted and unadjusted treatment response stratified by the whole cohort, SARD, and non-SARD subgroups

From: Serum inflammatory markers as predictors of therapeutic response in non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease: a retrospective cohort analysis

Outcomes

High inflammatory markers group

Low to normal inflammatory markers group

p-value

All treated patients

(N = 167), N (%); OR [95% CI]

58 (55.8%)

22 (34.9%)

0.011

OR 2.35 [1.23–4.48]

0.010

OR* 2.45 [1.24–4.83]

0.010

Treated patients with underlying SARDs (N = 96), N (%); OR [95% CI]

38 (61.2%)

16 (47%)

0.202

OR 1.78 [0.77–4.15]

0.181

OR* 2.05 [0.81–5.14]

0.125

Treated patients without underlying SARDs (N = 71), N (%); OR [95% CI]

20 (47.6%)

6 (20.7%)

0.026

OR 3.48 [1.18–10.3]

0.024

OR* 3.49 [1.14–10.71]

0.029

  1. *Adjusted odd ratio with age, sex, duration of treatment at response evaluation, and baseline FVC (%predicted)
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us